•
Mar 31, 2020

Edgewise Therapeutics Q1 2020 Earnings Report

EPS
-$0.157
Research and development expenses
$3M
General and administrative expenses
$300K
Gross Profit
$0

Edgewise Therapeutics

Edgewise Therapeutics